利福昔明联合复合乳酸菌胶囊治疗感染后肠易激综合征

发布时间：2018-02-02 14:36

本文关键词： 利福昔明复合乳酸菌胶囊感染后肠易激综合征小肠细菌过度生长　出处：《中国新药杂志》2016年12期 　论文类型：期刊论文

【摘要】：目的:探讨利福昔明联合复合乳酸菌胶囊对感染后肠易激综合征(post-infection irritable bowel syndrome,PI-IBS)的临床疗效。方法:选取2014年1月至2015年6月就诊我院消化内科80例PI-IBS患者作为研究对象,随机分为试验组和对照组各40例,对照组接受4周马来酸曲美布汀片、复合乳酸菌胶囊治疗,试验组接受2周利福昔明片、马来酸曲美布汀片及复合乳酸菌胶囊治疗后停用利福昔明片,继续2周马来酸曲美布汀片和复合乳酸菌胶囊治疗,观察两组治疗前后症状程度评分、血清炎性因子浓度变化,比较两组治疗总有效率、小肠细菌过度生长转阴率和不良反应发生率。结果:两组治疗后症状程度评分明显低于治疗前(P0.05),且试验组治疗后症状程度评分明显低于对照组治疗后症状程度评分(P0.05);两组治疗后血清促炎因子(IL-1β,IL-18)浓度明显低于治疗前(P0.05),抑炎因子IL-10浓度明显高于治疗前(P0.05),两组之间比较,试验组治疗后促炎因子(IL-1β,IL-18)浓度明显低于对照组(P0.05),抑炎因子IL-10浓度明显高于对照组(P0.05);试验组治疗总有效率和小肠细菌过度生长转阴率均明显高于对照组(P0.05);不良反应发生率两组差异无统计学意义(7.5%vs 5.0%,P0.05)。结论:利福昔明联合复合乳酸菌胶囊治疗感染后肠易激综合征,能够明显缓解临床症状,降低血清促炎因子浓度,升高抑炎因子浓度,提高治疗总有效率和小肠细菌过度生长转阴率,安全有效。
[Abstract]:Objective: to study the effect of rifaximin combined with lactic acid bacteria capsule on post-infection irritable bowel syndrome of irritable bowel syndrome. Methods: from January 2014 to June 2015, 80 patients with PI-IBS in the Department of Gastroenterology in our hospital were selected as the study objects. They were randomly divided into two groups: the experimental group (n = 40) and the control group (n = 40). The control group received trimebutine maleate tablets for 4 weeks, and the experimental group received rifamethoxifen tablets for 2 weeks. Trimebutine maleate tablets and compound lactobacillus capsules were treated with trimebutine maleate and compound lactobacillus capsules for 2 weeks. The change of serum inflammatory factor concentration was compared with the total effective rate of the two groups. Results: the symptom score of the two groups after treatment was significantly lower than that before treatment (P 0.05). The scores of symptom degree after treatment in the test group were significantly lower than those in the control group (P 0.05). After treatment, the concentration of IL-1 尾 -IL-18 in serum of both groups was significantly lower than that before treatment, and the concentration of anti-inflammatory factor IL-10 was significantly higher than that of pre-treatment (P0.05). After treatment, the concentration of IL-1 尾 -IL-18 in the experimental group was significantly lower than that in the control group (P0.05). The concentration of anti-inflammatory factor IL-10 was significantly higher than that of control group (P 0.05). The total effective rate and overgrowth rate of intestinal bacteria in the experimental group were significantly higher than those in the control group (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: rifaximin combined with Lactobacillus capsule is effective in the treatment of irritable bowel syndrome after infection. It can obviously relieve the clinical symptoms, reduce the concentration of serum proinflammatory factor, increase the concentration of anti-inflammatory factor, improve the total effective rate of treatment and the rate of overgrowth of intestinal bacteria to negative, which is safe and effective.
【作者单位】：安徽医科大学海军临床学院;中国人民解放军海军总医院消化内科;
【基金】：吴阶平临床科研专项基金资助项目(320.6750.13175)
【分类号】：R574
【正文快照】： 肠易激综合征(irritable bowel syndrome,IBS)是一种常见的慢性功能性胃肠病(functional gastroin-testinal disorders,FGIDs),临床特征为腹痛、腹胀等腹部不适,同时伴大便习惯和(或)大便性状改变,而完善现有的一切检查手段后未能发现可解释上述症状的任何生化及解剖结构异常[

【相似文献】